London, UK and New York, USA, 23 April 2015: MRC Technology, an independent life science medical research charity, and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown).
Drs Bruce Cronstein and Kathryn Moore of NYU School of Medicine have identified key proteins expressed on the surface of osteoclasts in the progression of inflammatory osteolysis. MRC Technology has extensive experience in antibody engineering and under the agreement will generate lead antibodies for testing in osteolysis models, before delivering a candidate antibody with acceptable efficacy in vivo.
Dr Nadim Shohdy, Director, Drug Discovery Partnerships at NYU School of Medicine said: “Osteolysis affects about 20% of patients with orthopaedic prostheses, resulting in implant loosening and the need for revision surgeries. By combining the expertise of NYU School of Medicine in this area with that of MRC Technology, a leader in the discovery and development of antibody drugs, we aim to develop efficacious antibodies for patients with osteolysis that currently have few therapy options.”
Dr John Kelly, Associate Director, Business Development, MRC Technology said: “NYU School of Medicine has done extensive research and holds various patents for inhibiting osteolysis. Combined with our successful track record in antibody development to create therapies for a number of debilitating conditions, we are positive that we can help bring new treatments to patients.”
Financial terms have not been disclosed.
ENDS
Notes to Editors:
Contacts
Media enquiries
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0) 7771 730919
At MRC Technology
Liezel Tipper
PR and Communications Manager
E-mail: liezel.tipper@tech.mrc.ac.uk Phone: +44 (0)20 7391 2772
About MRC Technology
MRC Technology (www.mrctechnology.org) is an independent life science medical research charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application. Four of MRC Technology’s projects have led to approved drugs (Tysabri®, Actemra®, Entyvio®, Keytruda®) and the company has a strong pipeline in development.
Please note MRC Technology has been independent from the UK’s Medical Research Council (MRC) since 2000.
About NYU School of Medicine
NYU School of Medicine (http://school.med.nyu.edu/) is one of the nation’s preeminent academic institutions dedicated to achieving medical education excellence. For 170 years, NYU School of Medicine has trained thousands of physicians and scientists who have helped to shape the course of medical history and enrich the lives of countless people. NYU School of Medicine has approximately $260 million in annual research funding and is a leader amongst universities in developing numerous biomedical products including blockbuster drugs on the market that have been used to treat almost two million patients worldwide.
Help employers find you! Check out all the jobs and post your resume.
